Início › Linfoma Não Hodgkin › Washington › Seattle
Ensaios clínicos de Linfoma Não Hodgkin em Seattle, WA
16 estudos para Linfoma Não Hodgkin estão buscando participantes em locais em Seattle e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecrutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecrutandoFase 2
- Swedish Cancer Institute, Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecrutandoFase 1
- Swedish Cancer Institute (SCI), Seattle
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
RecrutandoFase 1
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance), Seattle
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecrutandoFase 1/2
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
RecrutandoFase 1
- Fred Hutch Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecrutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
RecrutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecrutandoEstudo observacional
- Fred Hutchinson Cancer Research Center, Seattle
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
RecrutandoFase 1/2
- University of Washington Medical Center, Seattle
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RecrutandoEstudo observacional
- Kaiser Permanente Washington, Seattle
- Swedish Medical Center-First Hill, Seattle
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
RecrutandoFase 4
- Swedish Cancer Institute, Seattle
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
RecrutandoFase 4
- Swedish Cancer Institute, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
RecrutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
RecrutandoFase 1
- Swedish Cancer Institute, Seattle
Ensaios de Linfoma Não Hodgkin em outras cidades
- New York City, NY31 estudos
- Houston, TX31 estudos
- Boston, MA26 estudos
- Nashville, TN21 estudos
- Philadelphia, PA20 estudos
- Baldwin Park, CA19 estudos
- Washington, DC18 estudos
- Chicago, IL18 estudos
- Atlanta, GA18 estudos
- Milwaukee, WI18 estudos
- Columbus, OH18 estudos
- Dallas, TX17 estudos
Outros estudos em Seattle
- Câncer de Pulmão de Não Pequenas Células53 estudos
- Câncer (todos os tipos)49 estudos
- Câncer de Próstata42 estudos
- Leucemia Mieloide Aguda41 estudos
- Câncer de Mama39 estudos
- Câncer Metastático39 estudos
- Câncer Colorretal34 estudos
- Câncer de Pulmão33 estudos
- Câncer de Ovário30 estudos
- Mieloma Múltiplo22 estudos
- Câncer de Bexiga21 estudos
- Síndromes Mielodisplásicas21 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.